Abstract
584P - Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have